Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV

NCT00198393 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Gefitinib
DRUG: gemcitabine
DRUG: Docetaxel

Sponsor

Intergroupe Francophone de Cancerologie Thoracique

Collaborators

[object Object]
[object Object]